Keywords
How to Cite
Abstract
The purpose - was to perform a meta-analysis based on the results of randomized controlled trials that examined the efficacy and safety of using anti-VEGF (vascular endothelial growth factor (vascular endothelial growth factor, VEGF)) drugs as an auxiliary treatment for patients with glioblastoma (GBM).
Material and methods. A search for randomized controlled trials was conducted in the Pubmed, EMBASE, eLibrary and Cohrane Library databases published from January 2008 to March 2019, which examined the efficacy and safety of using anti-VEGF agents as an auxiliary method of treating GBM patients. The odds ratio (OR) and 95% confidence interval (CI) were used to calculate the overall survival and progression-free survival values.
Results. According to the eligibility criteria, 9 randomized controlled trials included in this meta-analysis that examine the results of using anti-VEGF drugs in 3189 patients with GBM. The overall survival rates of patients with GBM using anti-VEGF therapy exceed those in the group of patients with standard therapy without statistically significant differences (OR=0.89, 95% CI: 0.76, 1.04, p=0.13). Significant differences in progression-free survival were noted in favor of anti-VEGF agents (OR=0.70, 95% CI: 0.60, 0.82, p<0.00001). The performed subgroup analysis showed the absence of a statistically significant effect of bevacizumab on the overall survival rates of patients with GBM (OR=0.89, 95% CI: 0.75, 1.06, p=0.20). Using a combination of bevacizumab and standard therapy can significantly improve the progression-free survival rates in patients with GBM (OR=0.63, 95% CI: 0.51, 0.78, p<0.0001).
Conclusion. The performed meta-analysis clearly demonstrated that the combination of anti-VEGF agents and standard therapy does not significantly increase the overall survival rate of patients with GBM. However, the use of anti-VEGF drugs statistically significantly improves the values of progression-free survival in patients with GBM.
References
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al. (2015) CBTRUs statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17 Suppl 4:iv1-iv62.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, ohgaki H, Wiestler oD, Kleihues P, Ellison DW (2016) The 2016 World Health organization Classification of tumors of the Central Nervous system: a summary. Acta Neuropathol 131:803-820.
Batash R, Asna N, Schaffer P, Francis N, Schaffer M (2017) Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. Curr Med Chem 24(27):3002-3009.
Tosoni A, Franceschi E, Poggi R, Brandes AA (2016) Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. Curr Treat Options Oncol 17(9):49.
Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232(2):165-177.
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 6;310(17):1842-1850.
Бывальцев В.А., Степанов И.А., Белых Е.Г., Яруллина А.И. (2017) Молекулярные аспекты ангиогенеза в глиобластомах головного мозга. Вопр онкол 1:19-27.
Lin M, Zhang X, Jia B, Guan S (2018) Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2. J Neurooncol 136(2):243-254.
Zhao H, Hou C, Hou A, Zhu D (2016) Concurrent Expression of VEGF-C and Neuropilin-2 Is Correlated with Poor Prognosis in Glioblastoma. Tohoku J Exp Med 238(2):85-91.
Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591.
Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Rev Clin Oncol 6:24-40.
Balana C, De Las Penas R, Seplveda JM, Gil-Gil MJ, Luque R, Gallego O et al. (2016) Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neuro-Oncol 127:569-579.
Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212-3218.
Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, et al. (2015) Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology 17:708-717.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, G0tzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1-34.
Chinot OL, WickW, Mason W, Henriksson R, Saran F, Nishikawa R, et al. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722.
Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, et al. (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943-953.
Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 10;34(14):1611-1619.
Laack NN, Galanis E, Anderson SK, Leinweber C, Buckner JC, Giannini C, et al. (2015) Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance). Journal of Clinical Oncology 20;33(15):2013-2013.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. (2017). Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377(20):1954-1963.
Braun K, Ahluwalia MS (2017) Treatment of Glioblastoma in Older Adults. Curr Oncol Rep 19(12):81.
Hundsberger T, Reardon DA, Wen PY (2017) Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 17(6):507-515.
Gilbert MR (2016) Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results. J Clin Oncol 34(14):1567-1569.
Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec;16(12):1895-1908.
Duerinck J, Du Four S, Vandervorst F, D’Haene N, Le Mercier M, Michotte A et al. (2016) Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. J Neuro-Oncol 128:147-155.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740.
Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, et al. (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. NeuroOncology 17:1504-1513.
Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, et al. (2017) Randomized, doubleblind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O 6-methylguanine-DNA met. J Clin Oncol 35:343-351.
Xiao Q, Yang S, Ding G, Luo M (2018) Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis. Neurol Sci 39(12):2021-2031.
Lombardi G, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro L, et al. (2017) Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 111:94-102.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019